Study On The Prognosis Of Patients With ACS With Heart Failure By Health Management Network Platform

Objective to explore the health management platform for acute coronary syndrome(ACS)complicated with heart failure patient outcomes research,through the health management network platform of the guidance,more patients in the intervention before and after the intervention in the correlation of different indexes change,explore its in ACS patients complicated with heart failure(HF)and the clinical significance of the prognosis,It aims to improve the life cycle of patients with ACS complicated by HF,and improve the quality of life of patients,and play a certain auxiliary guiding role in the follow-up diagnosis,treatment and prevention of patients.Methods This study collected 568 patients diagnosed with ACS and HF from the emergency ward of the Qingdao University Affiliated Hospital from December 2018 to December 2020.Among them,8 patients were lost to follow-up due to living in other places,treatment in other hospitals or various reasons.A total of 560 patients were followed up for 1 year.Patients were divided into control group(n=280)and study group(n=280)according to the randomized controlled trial.In the control group,routine outpatient follow-up and self-management were performed after hospital treatment and stable discharge after drug treatment.In the research group,based on the treatment in the control group,the management of the network platform was carried out,and the basic information of patients,test and examination data,abnormal limits of monitoring indexes,and target value limits were collected.Health follow-up and discharge medication guidance were carried out for enrolled patients through telephone or We Chat and group chat,under the guidance of the network platform as the carrier of intervention,remote monitoring was carried out,regular outpatient follow-up was urged,and patients’ awareness of return visit,self-management awareness and health education behavior were enhanced.Observation indexes(1)entry team compared with general clinical basic information between the control(including gender,age,history of drinking,smoking history,family history of hyperlipidemia,hypertension,diabetes,etc.);(2)to compare two groups of patients before treatment respectively before and after discharge the first,third,sixth,and 12 months follow-up monitoring patients NT-pro BNP,、LVEF、LVEDD、LVESD 、 6MWD;(3)The incidence of major adverse cardiovascular events(MACE)(major indicators: recurrence of acute coronary syndrome,recurrence of heart failure,malignant arrhythmia,cerebrovascular disease and all-cause death)was compared between the two groups after discharge.Results(1)The control group with general data have no obvious differences between the study group,and not statistically significant(P>0.05);(2)The blood NT-Pro BNP and LVEF,LVEDD,LVESD and 6MWD in the first,third,sixth and twelfth month follow-up after discharge in the two groups were significantly improved compared with those before treatment,and the difference was statistically significant(P<0.05);(3)After 1,3,6 and 12 months under the guidance of intervention,the blood levels of NT-Pro BNP and LVEF,LVEDD,LVESD and 6MWD in the study group and the control group were significantly improved,and the difference was statistically significant(P<0.05);(4)Within 12 months of intervention guided treatment,the frequency of MACE in the study group was significantly lower than that in the control group,and the difference was statistically significant(P < 0.05).Conclusion During the follow-up of patients,under the guidance and intervention of the network platform,the indicators of LVEF,LVEDD,LVESD and 6MWD in cardiac ultrasound and plasma NT-Pro BNP in the follow-up patients of the study group were significantly improved compared with those in the non-intervention group.On the other hand,with the intervention of the network platform,the incidence of MACE in the intervention group was significantly lower than that in the control group.Therefore,in clinical practice,the health management network platform can improve the prognosis of patients with ACS complicated with heart failure,make their quality of life significantly better than before,and also reduce the hospitalization frequency of the patients,slow down the deterioration of the disease,which has a certain guiding effect on the prognosis of patients with ACS complicated with HF.